Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
Johnson & Johnson (NYSE:JNJ) is reportedly negotiating with plaintiffs' lawyers who have opposed its proposed $6.48 billion settlement over claims that its talc-based baby powder and other products cause cancer.
据报道，强生公司（NYSE:JNJ）正在与反对其涉嫌滑石粉婴儿爽身粉及其其他产品致癌的索赔案的原告律师进行谈判，以解决预计68.4亿美元的和解协议。
What Happened: Per a Reuters report, the New Brunswick, New Jersey-based company aims to resolve the remaining holdouts as it seeks to finalize the deal through the bankruptcy of a subsidiary following setbacks in federal courts.
据路透社报道，这家总部位于新泽西州新不伦瑞克的公司计划通过其子公司的破产解决剩余的诉讼问题，以便终结协议。公司在联邦法院遭遇挫折之后希望解决剩余的持不同意见的人。
Johnson & Johnson has temporarily paused the voting process to gather more votes from plaintiffs who have been resistant.
强生公司已暂停表决过程，以收集更多持反对意见的索赔人的票数。
Also Read: JohnsonA & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave.
还阅读：强生公司达成17亿美元交易收购心脏技术创新公司V-Wave。
"We have agreed to a short extension of the certification timeline," said Erik Haas, Johnson & Johnson's worldwide vice president of litigation, said Friday. "This will allow these plaintiffs' attorneys time to speak to their claimants to now consider supporting the plan."
强生公司全球诉讼副总裁埃里克·哈斯（Erik Haas）表示：“我们已经同意将认证时间表短暂延长。这将使这些原告律师有时间与他们的原告沟通，考虑支持该计划。”
The company plans to place a subsidiary into bankruptcy if at least 75% of the claimants agree to the settlement proposal.
如果至少有75%的索赔人同意和解提议，该公司计划将一个子公司放入破产。
The settlement would resolve all current talc-related lawsuits and prevent future cases that allege that Johnson & Johnson's products cause ovarian cancer and other illnesses.
该和解协议将解决所有与滑石粉相关的诉讼，并防止未来声称强生公司产品导致卵巢癌和其他疾病的案件。
Attorney Andy Birchfield, a key opponent of Johnson & Johnson's bankruptcy strategy, expressed openness to further negotiations but emphasized that he remains ready to challenge another Chapter 11 filing if necessary.
反对强生公司破产策略的主要对手律师安迪·伯奇菲尔德（Andy Birchfield）表示愿意进行进一步的谈判，但强调如果有必要他仍准备挑战另一起第11章破产申请。
Why It Maters: Johnson & Johnson is currently facing lawsuits from over 62,000 plaintiffs who claim that the company's talc products were contaminated with asbestos, leading to cancer diagnoses.
重要性：强生公司目前面临来自超过62,000名原告的诉讼，他们声称该公司的滑石粉产品被石棉污染，导致患癌症的诊断。
In May, Johnson & Johnson announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ovarian cancer arising from cosmetic talc litigation.
今年5月，强生公司宣布打算进行一项64.75亿美元的和解，以解决与化妆用滑石粉诉讼相关的众多卵巢癌诉讼。
The company has already paid approximately $5 billion to settle talc-related claims, including those involving mesothelioma and other cancers and allegations of illegal marketing practices by U.S. states.
该公司已经支付了约50亿美元来解决涉及滑石粉的索赔，包括那些涉及间皮瘤和其他癌症以及美国各州非法营销行为的指控。
Reuters cited internal documents and memos, including deposition and past trial testimonies, that show how Johnson & Johnson withheld info on the trace amounts of asbestos from regulators and the public for decades.
路透社引用内部文件和备忘录，包括证言和过去的审判证词，显示强生公司几十年来对石棉微量元素的信息对监管机构和公众进行了隐瞒。
Price Action: JNJ closed at $164.13 on Friday.
股价走势：JNJ上周五收盘报164.13美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
- 西门子医疗将以2.2亿美元的价格收购诺华诊断业务，以加强其癌症扫描业务。